Penobscot Investment Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-894
Closed -$211K 192
2019
Q1
$211K Sell
894
-483
-35% -$152K 0.04% 188
2018
Q4
$415K Sell
1,377
-180
-12% -$57.4K 0.1% 138
2018
Q3
$550K Sell
1,557
-220
-12% -$75.7K 0.12% 141
2018
Q2
$516K Sell
1,777
-660
-27% -$186K 0.12% 144
2018
Q1
$668K Buy
2,437
+1,613
+196% +$501K 0.16% 130
2017
Q4
$262K Hold
824
0.07% 171
2017
Q3
$258K Hold
824
0.08% 167
2017
Q2
$223K Buy
824
+75
+10% +$19.8K 0.07% 176
2017
Q1
$205K Hold
749
0.07% 177
2016
Q4
$212K Hold
749
0.07% 171
2016
Q3
$235K Buy
+749
New +$222K 0.08% 164
2016
Q1
Sell
-812
Closed -$249K 177
2015
Q4
$249K Buy
812
+23
+3% +$6.61K 0.08% 167
2015
Q3
$230K Hold
789
0.08% 178
2015
Q2
$319K Hold
789
0.1% 162
2015
Q1
$333K Hold
789
0.11% 153
2014
Q4
$268K Sell
789
-50
-6% -$16.2K 0.08% 164
2014
Q3
$278K Hold
839
0.09% 148
2014
Q2
$265K Hold
839
0.09% 152
2014
Q1
$257K Sell
839
-50
-6% -$15.9K 0.09% 153
2013
Q4
$249K Hold
889
0.09% 152
2013
Q3
$214K Sell
889
-50
-5% -$11.2K 0.08% 154
2013
Q2
$202K Buy
+939
New +$201K 0.08% 151

Other funds holding BIIB

Penobscot Investment Management's BIIB Position: Q2 2019 in Review

Penobscot Investment Management sold out of Biogen (BIIB) in Q2 2019, closing a stake of 894 shares — an estimated $211K sold.

Penobscot Investment Management first reported a position in BIIB in Q2 2013 and held it in 22 quarters. The position peaked at $668K in Q1 2018. 1,010 funds tracked by Wall St. Rank hold BIIB as of Q2 2019.

  • Penobscot Investment Management reported no remaining Biogen position as of Q2 2019 after selling out during the quarter.
  • Penobscot Investment Management sold 894 Biogen shares in Q2 2019, an estimated $211K.
  • Penobscot Investment Management first reported a position in Biogen in Q2 2013 and held it in 22 quarters.
  • Penobscot Investment Management's Biogen position peaked at $668K in Q1 2018.
  • 1,010 funds tracked by Wall St. Rank held Biogen as of Q2 2019.

Based on Penobscot Investment Management's 13F filing for Q2 2019, filed 2 Aug 2019.